Effects of bone remodeling agents following teriparatide treatment
- 23 Downloads
Teriparatide is an anabolic therapy used to treat patients with osteoporosis and is only approved for 2 years of treatment. This is the first study to look at two common osteoporosis drugs in maintaining its beneficial effects: denosumab and zoledronic acid. Denosumab treatment was associated with the greatest increase in bone mineral density (BMD) at the femoral neck and lumbar spine, an amount that was statistically greater than no treatment and zoledronic acid treatment.
Teriparatide, a hallmark treatment for osteoporosis, has been shown to increase BMD and bone turnover. This can be measured using BMD scans, N-terminal propeptide of type-1 collagen (P1NP) for bone formation and C-terminal telopeptide (CTX) for bone resorption. This study examines the effects of the two most common antiresorptive drugs prescribed following 2 years of teriparatide treatment: zoledronic acid and denosumab. The purpose of this study is to quantify the beneficial effects of teriparatide and compare the ability of each antiresorptive drug to maintain the effects.
Ninety-four patients with prior fragility fractures were identified from a bone health clinic associated with a level I trauma center. All of the study participants completed 2 years of treatment with teriparatide between 2008 and 2013 followed by 2 years of treatment with zoledronic acid, denosumab, or no treatment. After excluding patients with insufficient laboratory data, 64 patients remained for analysis in this retrospective cohort study. Bone mineral density was measured in the lumbar spine and femoral neck.
Following completion of teriparatide, patients who were started on denosumab showed the largest increase in bone mineral density after 2 years of treatment: lumbar spine 4.94% ± 8.2%, femoral neck 5.68% ± 6.7%.
Patients who elected to discontinue osteoporosis treatment experienced a significant decline in the change in BMD compared to the change on teriparatide putting them at higher risk for recurrence of fragility fractures. Patients on denosumab following teriparatide had the largest increase in BMD.
KeywordsAnabolics Antiresorptives Biochemical markers of bone turnover DXA Osteoporosis
The authors would like to gratefully acknowledge the invaluable assistance of Alan Shoemaker, PhD, and Alan Davis, PhD, for statistical consultation and analysis. Further, we would like to acknowledge Ms. Lindsey Behrend for her countless contributions to this project.
Compliance with ethical standards
This study was approved by the Spectrum Health Institutional Review Board.
Conflicts of interest
- 3.Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in post-menopausal women with osteoporosis. N Engl J Med 344:1434–1441CrossRefPubMedGoogle Scholar
- 18.Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie SAM, Zhu Y, Foley K, Lee H, Neer RM (2014) Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (the DATA Extension study): a randomized controlled trial. J Clin Endocrinol Metab 99(5):1694–1700CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB (2005) Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962–970Google Scholar
- 20.Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste-Marie LG, Gallagher JC, Pavo I, Wang J, Eriksen EF (2005) Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 90:3970–3977Google Scholar
- 21.Blumsohn A, Marin F, Nickelsen T, González de la Vera J, Boonen S, Liu-Léage S, Barker C, Eastell R (2011) Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide. Osteoporos Int 22(6):1935–1946Google Scholar
- 25.Brown JP, Roux C, Törring O, Ho PR, Beck Jensen JE, Gilchrist N, Recknor C, Austin M, Wang A, Grauer A, Wagman RB (2013) Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. J Bone Miner Res 28:746–752CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Bone HG, Brandi ML, Brown JP et al (2015) Ten years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension trial. Annual meeting of the American Society for Bone and Mineral Research (ASBMR), October 9–12. Seattle, USAGoogle Scholar
- 28.Cummings SR, Ferrari S, Eastell R et al. (2017) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM Trial and its extension. J Bone Miner Res. Epub. https://doi.org/10.1002/jbmr.3337